The effect of clinical services provided by a pharmacist to 25 study patients with essential hypertension was evaluated and compared to the course followed by 25 control hypertensive patients not receiving these services. Results show a significant improvement (P < 0.001) in the study patients' knowledge of hypertension and its treatment, a significant increase (P < 0.001) in the number of study patients who complied with prescribed therapy, and a significant increase (P < 0.001) in the number of study patients whose blood pressures were kept within the normal range during the study period. Most of these study patients had been hypertensive and noncompliant before, and they reverted to this status after the study period. The 25 control patients were hypertensive and noncompliant before, during, and after the study period. 
SUMMARY
The effect of clinical services provided by a pharmacist to 25 study patients with essential hypertension was evaluated and compared to the course followed by 25 control hypertensive patients not receiving these services. Results show a significant improvement (P < 0.001) in the study patients' knowledge of hypertension and its treatment, a significant increase (P < 0.001) in the number of study patients who complied with prescribed therapy, and a significant increase (P < 0.001) in the number of study patients whose blood pressures were kept within the normal range during the study period. Most of these study patients had been hypertensive and noncompliant before, and they reverted to this status after the study period. The 25 control patients were hypertensive and noncompliant before, during, and after the study period. Fifty-nine incidents of suspected adverse reactions to antihypertensive drugs were identified in the study patients Probably more than 25 million Americans are hypertensive. [7] [8] [9] [10] Sheer numbers reflect the magnitude of the problem facing the present health care system. Detection, diagnostic and treatment facilities, and medical personnel cannot adequately manage this caseload. Even when the condition is detected, patients are frequently lost to follow-up. 8 They often fail to follow prescribed drug therapy. 2 3 Inaccessibility or unavailability of facilities, high costs of medical and pharmaceutical care, lack of continuity of care, prolonged wait-ing times, lack of patient motivation, lack of patient education programs, and adverse reactions to antihypertensive drugs all could contribute significantly to this problem of noncompliance. 8' 12, 13 A number of authors have suggested that nonphysician health personnel can provide many services traditionally offered only by physicians. 9 10, 14-16 One such group of nonphysician health care personnel is pharmacists. Since the adequate care of hypertensive patients depends on use of antihypertensive drugs, more professional involvement of well-motivated and trained pharmacists should benefit hypertensive patients.
This study was completed 1) to identify the health care needs of the ambulatory hypertensive patients served by a comprehensive health service, The information on hypertension was presented to study patients in a structured and individualized manner. Pamphlets were handed out that reinforced discussions with the patients. Control patients were talked to by the physician or other health center personnel. Commercial hypertension literature was available to these patients and physicians throughout the study period at the health center.
The following definitions were used in this study: The test results of the control and study group patients completing the questionnaire were compared. We found that patients generally were poorly informed about hypertension and its treatment. Control patients continued to miss the same average number of responses to the 21-question test before and after the study period (table 2). The patients in the study group significantly improved the number of correct responses at the end of the study period. It should be noted that the individual increase in knowledge is probably higher since two patients in the study group accounted for 50% of the incorrect responses made by the group after the study period. These two patients missed the most appointments with the pharmacist investigator and were the least compliant with the recommended therapy.
A one-way analysis of variance on the differences in correct responses demonstrated by 15 control group patients and 19 study group patients before and after the study period showed that there was a significant difference [F(1, 32) =23.407; P < 0.00 (1] between the two groups. It is concluded that this difference is due to the services provided by the pharmacist investigator and that this service was effective in increasing the study patients knowledge of hypertension and its treatment.
Compliance with Prescribed Therapy
Patients in both the study and control groups were noncompliant with prescribed therapy during the seven month period prior to the study phase (table 3) . Each of these patients took approximately 65% of the prescribed antihypertensive drug doses. Control patients remained noncompliant prior to, during, and after the study period. In contrast, during the period when they were being seen by the pharmacist, study patients closely followed the prescribed regimen. After the study Circulation, Volume XLVIII, November 1973 The 24 study patients were exposed to 35 antihypertensive drugs during the five month study period. Twenty-one patients were prescribed thiazide diuretics, two patients were prescribed spironolactone, one patient was prescribed reserpine, seven patients were prescribed alpha methyldopa, three patients were prescribed guanethidine, and one patient was prescribed propranolol. The pharmacist investigator detected 59 undesirable or unintended reactions (suspected adverse drug reactions) to the antihypertensive drug therapy during the study period (table 5) . These reactions were validated by a thorough history, physical examination or laboratory testing. Reactions to drugs other than antihypertensive drugs were infrequent and are not reported here.
Most of the suspected adverse drug reactions were mild and were managed by the pharmacist investigator. Some of these reactions (i.e., nocturia) may be considered trivial and not completely unexpected. However, since these reactions ap- The 24 study patients experienced an average of 2.5 suspected adverse drug reactions during the five month study period. All study patients experienced at least one reaction attributed to antihypertensive drug therapy. Data also showed that the greater the number of drugs administered and the more potent the antihypertensive drug administered, the greater the average incidence of drug reactions (table 6). The drug reaction incidence appeared to closely correlate with the patient's compliance and whether blood pressure was controlled. Table 7 shows that compliant patients and normotensive patients experienced less than half the average number of drug reactions experienced by noncompliant and hypertensive patients. No remarkable age differences were observed in the incidence of drug reactions in study patients. Table 8 shows that males and whites experienced drug reactions slightly more often.
Recommendations to Physicians
The pharmacist investigator was in close touch with the physician; they discussed together the pharmacist investigator's subjective and objective observations of the patients, his assessment of the patient's problems and therapeutic response, and hiis plan for further service with the physician.
During the study period the pharmacist investigator wrote approximately 75 communications which contained a total of 37 recommendations to the physicians. Nineteen laboratory tests were requested to assist in the diagnosis of suspected adverse drug reactions. This testing was requested only when the patient's subjective responses suggested potential drug reactions. Fourteen recommendations suggested an increase or decrease in the dosage of an antihypertensive drug or a change in the antihypertensive drug regimen. These recommendations were implemented and resulted in better control of the blood pressure or of possible drug reactions. Three recommendations suggested additional diet instruction for patients while one suggested an evaluation of chest pain in a patient.
Recommendations to Patients
Sixty-five recommendations were made by the pharmacist investigator to the 24 patients in the study group. Nonprescription drug products were recommended 11 times during the study period. Recommendations included cough and cold products for flu symptoms, antacid products for gastrointestinal symptoms, and analgesics for minor arthralgias and headaches. In each case, products were recommended only if the patient required Circulation, Volume XLVIII, November 1973 them. Choice of drugs was tailored to the patient's specific needs, avoiding those agents that might interfere with antihypertensive therapy. The majority of the recommendations were provided to manage suspected adverse drug reactions. Nausea ceased in two patients after pharmacist investigator suggested taking the drug with meals. Eight patients were advised to include potassium-rich foods in their diets or to abstain from certain salty foods when subjective complaints suggested that these measures were warranted. Eight patients experiencing bothersome nocturia were advised to take their second daily diuretic dose in the midafternoon rather than at bedtime. Orthostatic hypotension was relieved in three patients when the pharmacist investigator suggested raising the head of the bed, arising slowly in the morning, and avoiding situations causing symptoms.
Potential drug interactions prompted other recommendations. Six patients who took Phospho Soda, Alka Seltzer, Bromo Seltzer, and large doses of Maalox were advised to substitute other drug products which contained less sodium or to discontinue the use completely. Five patients taking sympathomimetic amines in cough and cold preparations or as appetite suppressants were advised to stop this self-medication. The reasons why this medicine could be harmful were explained to the patient. Two patients were found to be selfadministering drugs from previous prescriptions and were advised to discontinue their use.
Professional Time
It was found that the contact time per patient visit with the pharmacist investigator was very similar to that spent by the physician. The pharmacist investigator spent approximately 25 minutes with each patient during the initial visit while the physician scheduled 30 minute appointments for initial patient visits. Subsequent visits with each patient required approximately six minutes by the pharmacist investigator while the physician spent approximately five minutes for follow-up visits with hypertensive patients. These findings are important since it was not the purpose of this study to restrict the professional time spent with each patient, but to identify problems experienced by hypertensive patients and to find ways a pharmacist might assist the patient in the resolution of these problems.
It is also interesting to note that only 34 patient appointments with physicians were scheduled during the study period for study patients while this same group of patients were scheduled for 44 appointments during a similar time period before the study period. The differences may reflect better blood pressure control in study patients. Control patients were scheduled for 41 appointments before and 45 appointments after the study period. These data suggest that the pharmacist investigator's services may have decreased the need for intensive physician follow-up services.
Patient Acceptance Study patients were highly receptive to the clinical services offered by the pharmacist investigator. They answered yes to all three of the following questions: 1) Have these appointments been of benefit to you? 2) Should this service be offered to all hypertensive patients of MNCHP? 3) Should similar services be made available to you for other medical problems such as diabetes and heart disease? Also, study patients kept 92% of the 100 appointments made with the pharmacist investigator during the five month study period. Even though appointments were missed, no study patient was lost to medical or pharmaceutical follow-up during the study period. At the same time, appointments with physicians were kept 88% of the time among study patients and 82% of 44 physician appointments with control patients were kept. Five control patients were lost to medical or pharmaceutical follow-up during the study period.
Discussion and Conclusions
This study has shown that the clinical services provided by the pharmacist investigator to hypertensive patients were effective in improving treatment results. The services apparently answered needs of patients; some of the important factors that made this approach effective are discussed below.
Suspected adverse reactions to antihypertensive drugs produced frequent, undesirable symptoms in study patients and appeared to be one of the main reasons patients stopped taking their medicine. Many of these reactions were mild but had gone undetected, untreated, or unexplained. The pharmacist investigator actively solicited complaints from his patients about reactions they believed were caused by the drug. He made an immediate attempt to help the patient, fully explaining the nature of the problem and the plan of management.
Some hypertensive patients were taking other drugs, both prescription and nonprescription, at the same time that they were taking antihypertensive drugs. These November 1973 team members appeared to help assure successful treatment.
Patients were often reluctant or unable to talk freely with the physicians. Often they did not wish to bother the physician or take too much time with some complaint. They seldom called health personnel between appointments for advice. The pharmacist investigator described how the patient could make use of all facets of the health care system. He freely discussed problems with the patients and acted promptly on them. He was always accessible to the patients between appointments.
Finally, the effectiveness of treatment in this study probably was improved by the patient's association with a health professional who understood his disease, respected his needs, and took the time to discuss his problems and progress.
It is important to note that the waiting time of the patients to see physicians and pharmacists did not appear to be a significant problem, since the patients were seen by appointment. Everyone who came into the program was assessed according to his ability to pay; therefore the cost to the patienf was not a major influence determining the outcome of this study.
The data presented in this study suggests that a well trained and motivated clinical pharmacist can be an essential part of the health care team caring for hypertensive patients. His services appear to help insure the success of treatment and are acceptable to the patients receiving them. Since the treatment successes were generally lost after the pharmacist investigator's involvement ceased, the pharmacist's services must be continued indefinitely to be most effective. This study suggests that the pharmacist may successfully assume increased responsibility for the long term health care of patients with essential hypertension. This approach may partially relieve the physician manpower problem and increase the availability of the services we will need to adequately care for the millions of hypertensive patients yet to be detected, treated, or adequately treated. Further study of this approach with larger groups of patients and pharmacists is needed.
